SHIP OF THESEUS, LLC

Eagleville, PA

Oncologygene editingGrant-only

Compare Sign in to watch

What changed

NIH R01 · $0.7M · Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins

7mo agoGrant renewalDec 16, 2025Source filing (opens the source filing in a new tab)

Momentum

51no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R41 · $400k · non-dilutive
Sep 10, 2025
SHIP OF THESEUS, LLC · PI ELSER, JEREMY A · NCI · award ends Aug 31, 2027 · Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies
NIH RePORTER · NIH RePORTER 11314426 (opens the source filing in a new tab)
Grant
R01 · $724k · non-dilutive
Jan 21, 2023
UNIVERSITY OF PENNSYLVANIA · PI GILL, SAAR · NINDS · award ends Dec 31, 2027 · Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins
NIH RePORTER · NIH RePORTER 11251198 (opens the source filing in a new tab)
Grant
R44 · $1.8M · non-dilutive
Aug 10, 2021
SHIP OF THESEUS, LLC · PI ELSER, JEREMY A · NHLBI · award ends Jul 31, 2027 · Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant
NIH RePORTER · NIH RePORTER 11255048 (opens the source filing in a new tab)
Grant
P01 · $525k · non-dilutive
Aug 15, 2017
UNIVERSITY OF PENNSYLVANIA · PI GILL, SAAR · NCI · award ends Aug 31, 2028 · Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies
NIH RePORTER · NIH RePORTER 11192827 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 1.00name similarity 100% · semantic similarity 87% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.27same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.7M · Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins
7mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P01 · $0.5M · Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R41 · $0.4M · Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies
10mo agoNew grantSource (opens the source filing in a new tab)
NIH R44 · $1.8M · Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant
11mo agoGrant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R41 · $400k · non-dilutive

R01 · $724k · non-dilutive

R44 · $1.8M · non-dilutive

P01 · $525k · non-dilutive